Trial Profile
Mechanism of Action Study of Ustekinumab Treatment in Psoriatic Arthritis: Impact on Cellular and Molecular Pathways of Synovial Inflammation and Tissue Remodeling
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms MoA anti-p40
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 06 Jun 2020 Status changed to completed.
- 29 Jun 2018 New trial record